Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type abstract
PMID
Authors Yu-Yon Kim; Seung Hyun Jung; Seon Yeong Han; Jooyun Byun; Gunwoo Lee; Miyoung Lee; Junghwa Park; Taeyeon Kong; Hyesun Han; Sang Hyun Lee; Young Gil Ahn
Title Abstract 3240: Synthetic lethal strategy of an EZH1/2 dual inhibitor, HM97662, for the treatment of ARID1A-mutated solid cancers
Journal Vol Issue Date Pages Journal Short Title
Cancer Research 84 6_Supplement March 22, 2024
URL https://aacrjournals.org/cancerres/article/84/6_Supplement/3240/735951
Abstract Text Enhancer of zeste homolog 2 (EZH2), an enzymatic subunit of polycomb repressive complex 2 (PRC2), is known to catalyze tri-methylation of histone H3 at lysine 27 (H3K27me3), leading to repression of the transcription of its target genes involved in cell cycle regulation, cell proliferation, cell differentiation, and tumor suppression. It has been proposed that epigenetic regulators could serve as novel drug targets, and EZH2 is one of the targets with considerable therapeutic potential. Meanwhile, synthetic lethality is a phenomenon whereby individual genes in a pair can be knocked-out without affecting cell viability, while disruptions of both genes concurrently cause cell death. It has been shown that loss-of-function (LOF) mutations of component proteins in SWI-SNF chromatin remodeling complex, including PBRM1, ARID1A, SMARCA4, and so on, are synthetic lethal with inhibition of the histone methyltransferase EZH2. Especially, ARID1A-mutated solid tumors are vulnerable to EZH2 inhibition. Given that ARID1A is mutated in approximately 10% of all tumor types, inhibiting EZH2 activity could be a promising therapeutic strategy for cancer patients with this mutation. Although the methyltransferase activity of PRC2 is mainly contributed by EZH2, EZH1 also plays a compensatory role in maintaining tri-methylation of H3K27 and directly binds to chromatin, modulating its condensation. These emphasize that blocking both EZH1 and EZH2 might have greater anti-tumor effect than EZH2 alone. Herein, we introduce a novel EZH1/2 dual inhibitor, HM97662, which concurrently suppressed the methyltransferase activity not only wild-type EZH1, but also wild-type and gain-of-function (GOF) mutant EZH2 at nanomolar concentrations. HM97662 potently repressed tri-methylation of H3K27me3 in TOV-21G (ovarian cancer) and HT-1376 (bladder cancer) cell lines with ARID1A LOF mutation. HM97662 also showed a wide and strong growth inhibitory effect in various solid cancer cell lines harboring ARID1A mutation. HM97662 exhibited potent antitumor activities in xenograft mouse models with various ARID1A-mutated cancer cells including ovarian, bladder, small cell lung cancer, prostate, and gastric cancers (e.g. TOV-21G, HT-1197, NCI-H128, LNCap, and MKN-45, respectively). Once-daily oral dosing of HM97662 greatly inhibited tumor growth in a dose-dependent manner without significant clinical signs compared to known EZH2 selective or EZH1/2 dual inhibitors. HM97662 also exhibited a synergistic effect in combination with second-line standard of care in small cell lung cancer. In conclusion, these preclinical studies demonstrated that HM97662 as an EZH1/2 dual inhibitor, holds promising therapeutic potential for ARID1A-mutated solid cancers. It is crucial to evaluate the effectiveness of HM97662 in subsequent clinical trials.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ARID1A inact mut stomach cancer predicted - sensitive HM97662 Preclinical Actionable In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of gastric cancer harboring an ARID1A mutation (Cancer Res (2024) 84 (6_Supplement): 3240). detail...
ARID1A inact mut lung small cell carcinoma predicted - sensitive HM97662 Preclinical Actionable In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of small cell lung cancer harboring an ARID1A mutation (Cancer Res (2024) 84 (6_Supplement): 3240). detail...
ARID1A inact mut urinary bladder cancer predicted - sensitive HM97662 Preclinical Actionable In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of bladder cancer harboring an ARID1A loss-of-function mutation (Cancer Res (2024) 84 (6_Supplement): 3240). detail...
ARID1A inact mut prostate cancer predicted - sensitive HM97662 Preclinical Actionable In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of prostate cancer harboring an ARID1A mutation (Cancer Res (2024) 84 (6_Supplement): 3240). detail...
ARID1A inact mut ovarian cancer predicted - sensitive HM97662 Preclinical Actionable In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of ovarian cancer harboring an ARID1A loss-of-function mutation (Cancer Res (2024) 84 (6_Supplement): 3240). detail...